Lately, there's been a lot of talk about drones and their place in safeguarding America. And while there's still controversy surrounding their use, there's no denying that drones are an effective weapon of war -- both for spying, er "observation," and taking out enemy targets. They are so effective, in fact, that a new frontier is opening up to drone warfare -- namely, the sea. For both Raytheon (NYSE: RTN ) and SAIC (NYSE: SAI ) , this is good news.
Unmanned to the rescue
Right now there are an estimated 600 submarines from 43 countries that the Navy is responsible for tracking, according to Defense Advanced Research Projects Agency, or DARPA. Understandably, this isn't the cheapest venture for the Navy, but because of the potential security threat these subs pose, it's essential. Consequently, DARPA, along with Raytheon and SAIC, have teamed up to develop a cost-effective solution -- the Anti-Submarine Warfare Continuous Trail Unmanned Vehicle, or ACTUV.�
Hot Building Product Stocks To Watch Right Now: ManpowerGroup(MAN)
ManpowerGroup provides workforce solutions and services worldwide. The company offers permanent, temporary, and contract recruitment services; assessment and selection services; training and development services; outsourcing services; and workforce consulting services. It also provides professional resourcing and project-based workforce solutions in the information technology, finance, and engineering fields; talent and career management workforce solutions; and talent based outsourcing services, managed services, recruitment process outsourcing services, borderless talent solutions, and strategic workforce consulting services. The company was founded in 1948 and is headquartered in Milwaukee, Wisconsin.
Advisors' Opinion:- [By Jon C. Ogg]
ManpowerGroup Inc. (NYSE: MAN) was raised to Buy from Neutral and the price target was raised to $80 from $71 (versus a $73.11 close), based on encouraging signs on Europe’s macro front and also on impressive cost-cutting efforts, at Bank of America�Merrill Lynch.
- [By Dan Burrows]
Staffing stocks like Manpower Group (MAN), Robert Half International (RHI) and Kelly Services (KELYA) have put up market-beating to market-crushing gains over the last year, boosted by accelerating strength in the job market.
Top 10 Cheapest Companies To Buy For 2014: HeartWare International Inc (HTWR)
Heartware International, Inc. (HeartWare), incorporated on June 25, 2010, develops and manufactures small implantable heart pumps, or ventricular assist devices, for the treatment of advanced heart failure. The HeartWare Ventricular Assist System (the HeartWare System), which includes a ventricular assist device (VAD), or blood pump, patient accessories and surgical tools, is designed to provide circulatory support for patients in the advanced stage of heart failure. The core of the HeartWare System is a continuous flow blood pump, the HVAD Pump, which is a full-output device capable of pumping up to 10 liters of blood per minute. The HeartWare System is designed to be implanted adjacent to the heart, avoiding the abdominal surgery generally required to implant similar devices. In August 2012, it acquired World Heart Corporation. As of December 31, 2012, the HeartWare System has been implanted outside of the United States at approximately 168 health care sites in 28 countries. In December 2013, HeartWare International Inc acquired CircuLite, Inc.
Proprietary Pump Technology
The HeartWare System is full-output centrifugal pump designed to be implanted in the chest, directly adjacent to the heart. At the core of the Company�� technology platform is its hybrid system for suspending the impeller, which is the only moving part within the pump. The impeller is suspended within the pump housing by the opposing forces of passive magnets and hydrodynamic thrust generated by the pump impeller, which circulates a cushion of
blood. Once power is applied to the device and the impeller begins to rotate, there are no points of mechanical contact within the pump, thus providing a completely wearless pumping system.
The HeartWare System
The HeartWare System consists of the HVAD Pump, a small, permanently implantable VAD, patient accessories and surgical tools. The HVAD Pump is capable of generating up to 10 liters of blood flow per minute. With a displaced v! olume of only 50 cubic centimeters and a mass of 140 grams, the HVAD Pump is the only full-output pump implantable in the pericardial space, directly adjacent to the heart. It is also the only pump designed to be implanted above the diaphragm in all eligible patients.
The HeartWare MVAD
The miniaturized ventricular assist device (MVAD) is a miniaturized blood pump intended for chronic heart failure patients. The device is a full-output axial flow pump with a fully suspended rotor and a displacement volume approximately one-third that of the HVAD Pump.
The Company competes with Thoratec Corporation, Jarvik Heart, MicroMed Technology, Inc, Berlin Heart AG, Terumo Heart, Inc., Sunshine Heart, Inc and CircuLite, Inc., Evaheart Medical USA, Inc.
Advisors' Opinion:- [By Maria Armental var popups = dojo.query(".socialByline .popC"); popups.forEach]
HeartWare International Inc.(HTWR) said it received a warning letter from the U.S. Food and Drug Administration, citing concerns about procedures for validating device design and other issues.
- [By Lauren Pollock]
Medical device company HeartWare International Inc.(HTWR) issued a revenue forecast that fell short of market expectations.
Intrepid Potash Inc.(IPI), the largest potash producer in the U.S., plans to cut its workforce by 7% and cut executive compensation as part of a plan to trim costs in reaction to weaker prices for the fertilizer ingredient.
- [By Todd Campbell]
Competing for heart pump market share
Abiomed's products provide circulatory support for up to six hours and are designed for use in cardiac cath labs or during heart surgery, but competitors Thoratec (NASDAQ: THOR ) and Heartware (NASDAQ: HTWR ) target the intermediate- and long-term-use market instead.
Top 10 Cheapest Companies To Buy For 2014: Ambit Biosciences Corp (AMBI)
Ambit Biosciences Corporation, incorporated on May 17, 2000, is a biopharmaceutical company. The Company focused on the discovery, development and commercialization of drugs to treat unmet medical needs in oncology, autoimmune and inflammatory diseases by inhibiting kinases that are important drivers for those diseases. The Company�� lead drug candidate, quizartinib, is in Phase IIb clinical development in patients with relapsed/refractory acute myeloid leukemia (AML). The Company�� second drug candidate in clinical development, AC410, is a potent, selective, orally-administered, small molecule inhibitor of Janus kinase 2 (JAK2) that has potential utility for the treatment of autoimmune and inflammatory diseases. The Company�� third program consists of two selective small molecule compounds, AC708 and AC855, which inhibit the colony-stimulating factor-1 receptor (CSF1R), a receptor tyrosine kinase.
Quizartinib
The Company�� lead drug candidate, quizartinib, is a once-daily, orally-administered, potent and selective inhibitor of FLT3, a validated target in the treatment of AML, and is in Phase IIb clinical development. The FLT3-ITD mutation acts like a power switch that causes leukemic cells, or blasts, to spread more aggressively and grow back more rapidly following chemotherapy, conferring an especially poor survival outcome. Quizartinib is designed to turn off this switch. The Company is developing a companion diagnostic test with Genoptix Medical Laboratory, a Novartis company, to identify FLT3-ITD positive patients.
AC410
The Company�� advanced drug candidate, AC410, is a potent, selective, orally-administered, small molecule inhibitor of JAK2, which has potential utility for the treatment of autoimmune and inflammatory diseases. Signaling through JAK controls the activation, proliferation and survival of various types of immune cells, and overactivation of such cells can exacerbate a range of normal inflammatory processes, resulting i! n inflammation. The Company�� initial JAK2 drug candidate, AC430, is a racemic mixture (50/50) of two enantiomers (mirror images), AC410 and AC409, and was studied in a Phase I clinical trial.
CSF1R Program
The Company is developing two potent and exquisitely selective small molecule compounds, AC708 and AC855 that both inhibit CSF1R and have potential utility in oncology, autoimmune and inflammatory diseases. Signaling through CSF1R controls the activation, proliferation and survival of macrophages, which are key mediators of immune system function and over-activation of macrophages, may result in exacerbation of certain diseases.
The Company competes with Abbvie Inc., Akinion Pharmaceuticals AB, Amgen Inc., ARIAD Pharmaceuticals, Inc., AROG Pharmaceuticals, LLC, ArQule, Inc., Astellas, AstraZeneca plc, Bayer AG, Celgene Corporation, Daiichi-Sankyo Company Limited, Galapagos NV, GlaxoSmithKline plc, Incyte Corporation, Janssen Pharmaceuticals, Inc., Johnson & Johnson, Eli Lilly and Company, Novartis, Onyx Pharmaceuticals, Inc., Pfizer, Rigel Pharmaceuticals, Inc., F. Hoffman-LaRoche Ltd, and Vertex Pharmaceuticals Incorporated.
Advisors' Opinion:- [By Wallace Witkowski]
Ambit Biosciences Corp. (AMBI) �shares fell more than 37% to $8 in moderate volume. The small-cap biotech said it will not file an accelerated approval application with the Food and Drug Administration for its leukemia drug quizartinib after the agency disagreed with the company about the use of certain study data to support the drug�� efficacy.
Top 10 Cheapest Companies To Buy For 2014: VeriSign Inc.(VRSN)
VeriSign, Inc. provides Internet infrastructure services to various networks worldwide. The company provides domain name registry services and infrastructure assurance services. It offers registry services that operate the authoritative directory of various .com, .net, .cc, .tv, and .name domain names, as well as the back-end systems for various .jobs and .edu domain names; and network intelligence and availability services that provide infrastructure assurance to organizations comprising Verisign iDefense security intelligence services, managed domain name system services, and distributed denial of service mitigation. VeriSign, Inc. was founded in 1995 and is headquartered in Reston, Virginia.
Advisors' Opinion:- [By Monica Gerson]
VeriSign (NASDAQ: VRSN) is expected to post its Q3 earnings at $0.57 per share on revenue of $240.61 million.
Coca-Cola Enterprises (NYSE: CCE) is estimated to report its Q3 earnings at $0.80 per share on revenue of $2.16 billion.
- [By Ben Levisohn]
That leaves just five big losers that have kept on losing. Those would be Darden Restaurants (DRI), which has dropped 0.1% to $46.23 at 3:29.p.m., Jacobs Engineering Group (JEC), which has fallen 0.1% to $53.21, VeriSign (VRSN), which has declined 0.3% to $48.66, Express Scripts (ESRX), which is off 0.4% at $69.08, and Urban Outfitters (URBN), which has slipped 1.2% to $33.45.
Top 10 Cheapest Companies To Buy For 2014: Spherix Inc (SPEX)
Spherix Incorporated (Spherix), incorporated on May 1, 1992, is a scientific research company. The Company is engaged in developing biopharmaceutical products and providing technical and regulatory consulting services to food, consumer products and pharmaceutical companies. The Company operates in two segments: Biospherics Incorporated (Biospherics), the Company's biotechnology research and development business, and Health Sciences, a technical and regulatory consulting business. The Company has created two wholly owned subsidiaries, Biospherics Incorporated and Spherix Consulting, Inc. (Spherix Consulting), for its two operating segments. The Company's Health Sciences contracts are in the name of Spherix Consulting, and the Company's patents are in the name of Biospherics Incorporated. Spherix provides management, strategic guidance, business development, marketing and other services to its subsidiaries. In September 2013, Spherix Incorporated closed on the acquisition of North South Holdings Inc.
Biospherics
The Company focuses its studies on treating high triglycerides and other dyslipidemias with a combination of D-tagatose and SPX-106, a licensed drug compound, which combination is referred to as SPX-106T. Spherix Consulting provides scientific and strategic support for suppliers, manufacturers, distributors and retailers of conventional foods, biotechnology-derived foods, medical foods, infant formulas, food ingredients, dietary supplements, food contact substances, pharmaceuticals, medical devices, consumer products, and industrial chemicals and pesticides. Biospherics has also completed a global Phase III clinical trial investigating the use of D-Tagatose, a stereoisomer of fructose, as a treatment for glycemic control in patients with Type 2 diabetes.
Health Sciences
The Company's Health Sciences business provides technical and regulatory consulting services to biotechnology and pharmaceutical companies, as well as providing technical suppo! rt for its research and development activities. During the year ended December 31, 2011, Health Sciences provided services to 20 companies. The projects range from safety analyses of food ingredients to safety analyses of pharmaceutical manufacturing and dispensing equipment. Health Sciences is also monitoring and directing the clinical trials for Biospherics.
Advisors' Opinion:- [By Sue Chang and Ben Eisen]
SPEX: Spherix Inc. (SPEX) �shares rose 5% after the intellectual property development company said it had completed a $20 million equity financing that involved selling 10 million shares of convertible preferred stock.
- [By John Udovich]
Small cap patent stocks Spherix Inc (NASDAQ: SPEX), PDL BioPharma Inc (NASDAQ: PDLI) and Endeavor IP Inc (OTCBB: ENIP) are among the�growing number of publicly traded�US entities focused on collecting and making money from various types of patents. After all, monetizing patents can lead to incredible returns. For example: Nomura analyst Rick Sherlund wrote in a research note back in November that Microsoft Corporation (NASDAQ: MSFT) is generating $2 billion per year in revenue from Android patent royalties and he�estimates that this revenue has a 95% margin. However, there are risks associated with investing in stocks that invest in patents because a bi-partisan bill called the Innovation Act (H.R. 3309) is�working its way through Congress to try and reign in the activities of so-called�"patent trolls" or rather companies that buy or license patents from others.
- [By Susan Decker]
In more than two decades as a publicly-traded company, Spherix Inc. (SPEX) developed diabetes treatments, marketed a low-calorie sweetener and handled campground reservations. Now it�� dealing in something completely different: patents.
Top 10 Cheapest Companies To Buy For 2014: Bio-Reference Laboratories Inc.(BRLI)
Bio-Reference Laboratories, Inc. provides clinical laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases primarily in the greater New York metropolitan area. It offers various chemical diagnostic tests, including blood and urine analysis, blood chemistry, hematology services, serology, radio-immuno analysis, toxicology, pap smears, tissue pathology, and other tissue analysis. The company also operates a clinical knowledge management service unit, which uses customer data from laboratory results, pharmaceutical data, claims data, and other data sources to provide administrative and clinical decision support systems. In addition, it operates a Web-based connectivity portal solution for laboratories and physicians to provide laboratory ordering and results to physician customers. The company provides its services directly to physicians, geneticists, hospitals, clinics, and correctional and other health facilities. Bio-Refe rence Laboratories, Inc. was founded in 1981 and is headquartered in Elmwood Park, New Jersey.
Advisors' Opinion:- [By GuruFocus]
An example here is Bio Reference Lab (BRLI). This is a company with a simple business, strong balance sheet and the Predictability Rank of 5-Star. At the price of $19, BRLI was in the top of the Buffett-Munger Screener. But the stock price quickly dropped to below $12 in November 2011. At that point, the company announced a share buyback. The CEO, CFO and COO also bought shares in December at $14 a share. Since then the stock price has doubled.
- [By Geoff Gannon]
But if you can definitely hold a company through a tough market that lasts a few years ��then you can look for a wonderful business to buy and hold at any time. In any market. I found some lovely businesses around the time of the 2000 market peak. They just weren�� big caps, dot coms, etc. They were smaller more mundane businesses. In at least one case ��Bio-Reference Labs (BRLI) ��I made some money (it seemed like a scary big amount at the time) holding the stock for about 2 years but I would��e made a whole lot more if I had just held that one stock through till today. And even now BRLI seems a fine stock to keep holding. So, you see I could��e saved myself a lot of trouble by holding something for more than 10 years. And it wouldn�� have hurt my performance at all. In fact, BRLI has beaten the market by a lot for a very long time. And, yes, the price I paid for BRLI happens to be the most I ever paid for a stock relative to its record earnings. So, I paid a very high price ��for a value investor like me ��for a stock that promptly went on to return around 20% a year for the next 10 years and is now back at almost the exact same P/E ratio where I first bought it.
- [By Monica Gerson]
Bio-Reference Laboratories Inc (NASDAQ: BRLI) is projected to report its Q4 earnings at $0.63 per share on revenue of $228.81 million.
Posted-In: Earnings scheduleEarnings News Pre-Market Outlook Markets
Top 10 Cheapest Companies To Buy For 2014: GrowLife Inc (PHOT)
GrowLife, Inc., formerly, Phototron Holdings, Inc., incorporated on March 7, 2001, sells and distributse mini-hydroponic greenhouses (Phototron Units) and horticultural seeds, mineral nutrient solutions, growing mediums and germination kits. On February 14, 2011, the Company entered into an agreement and plan of merger (Merger Agreement) with PHI Merger Corporation and its wholly owned subsidiary (MergerCo), and Phototron, Inc., (Phototron). On March 9, 2011, MergerCo was merged with and into Phototron and Phototron became its wholly owned subsidiary. In May 2011, it announced the launch of its wholly owned direct selling hydroponic gardening subsidiary, GrowLife Inc. In April 2012, it merged with SG Technologies Corp. A newly formed subsidiary of the Company was merged with and into SG Technologies Corp. On July 23, 2012, the Company acquired Greners.com, related to the online retail business operated by Greners.
The Company designs and manufactures indoor mini-hydroponic greenhouses capable of growing almost any herb, vegetable, flower, fruit or terrestrial plant better, stronger and faster than traditional farming methods. Its Phototron Units, consisting of 21 inch x 39 inch units and 21 inch x 51 inch units, provide between 18,900 and 36,000 lumens of light. Phototron Units also allow users to control what a plant receives, grow crops densely, avoid using pesticides, increase yields and automatically water plants.
The Company also formulates and sells horticultural seeds, mineral nutrient solutions, growing mediums and germination kits to facilitate hydroponic gardening through the use of its Phototron Units. In addition, it designs and manufactures replacement parts for its Phototron Units to facilitate customization of the units. It owns a mailing list and have a customer base exceeding 50,000 people. Its re-order program, which involves the sale of nutrients and related products and replacement parts for Phototron Units, represents 50% of its revenue.
Advisors' Opinion:- [By John Udovich]
Its been a rather eventful week for news from the marijuana sector and small cap marijuana stocks like GW Pharmaceuticals PLC (NASDAQ: GWPH), Tranzbyte Corp (OTCMKTS: ERBB) and Growlife Inc (OTCMKTS: PHOT) as one of these stocks gets endorsed by Morgan Stanley while another appears on CNBC���more signs of legitimacy for an investment�sector that�� full of pumps, dumps and other unsavory types of activities. Just consider the following small cap marijuana stock or pot industry news:
- [By John Udovich]
The SEC has halted trading of small cap marijuana stock Growlife Inc (OTCMKTS: PHOT) after a relatively brief trading halt for�Advanced Cannabis Solutions, Inc (OTCMKTS: CANN), but Tranzbyte Corp (OTCMKTS: ERBB), Cannabis Science Inc (OTCMKTS: CBIS) and Medical Marijuana Inc (OTCMKTS: MJNA) are still very much alive. However and as I have noted (repeatedly)�in the past (see here), Medical Marijuana Inc has a�former CEO who has been indicted for a multi-state mortgage fraud scam/ponzi scheme while Medbox Inc (OTCMKTS: MDBX) is another marijuana stock with some ��ssues��that were summed up nicely in a Southern Investigative Reporting Foundation article cleverly entitled: Tinkerer, Lawyer, Hustler, Lies: One Man�� Path to a Dope Fortune. Obviously, investing in marijuana stocks is not for conservative. Nevertheless, there is�still plenty of good or bad news for investors in the marijuana sector to inhale, including the following:
No comments:
Post a Comment